Tsumura & Co. (TYO:4540)
3,810.00
+60.00 (1.60%)
May 29, 2026, 3:30 PM JST
Tsumura & Co. Revenue
In the fiscal year ending March 31, 2026, Tsumura & Co. had annual revenue of 192.62B JPY with 6.36% growth. Tsumura & Co. had revenue of 47.44B in the quarter ending March 31, 2026, with 7.04% growth.
Revenue
192.62B
Revenue Growth
+6.36%
P/S Ratio
1.47
Revenue / Employee
45.09M
Employees
4,272
Market Cap
284.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 192.62B | 11.52B | 6.36% |
| Mar 31, 2025 | 181.09B | 30.25B | 20.05% |
| Mar 31, 2024 | 150.85B | 10.80B | 7.71% |
| Mar 31, 2023 | 140.04B | 10.50B | 8.10% |
| Mar 31, 2022 | 129.55B | -1.34B | -1.02% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Toho Holdings | 1.55T |
| Sumitomo Pharma | 453.29B |
| Towa Pharmaceutical | 273.71B |
| Sawai Group Holdings | 201.68B |
| Nippon Shinyaku | 170.77B |
| KYORIN Pharmaceutical | 126.26B |
| Mochida Pharmaceutical | 116.95B |
| Kissei Pharmaceutical | 97.41B |